Pancreatic Cancer Research

ResearcherKagawa UniversityActive in the last 2 years

Hironobu Suto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8476-3985; OpenAlex author ID A5045666187. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 4 papers · 2023: 2 papers · 2024: 6 papers · 2025: 1 paper · 2026: 3 papers

Papers 21

  1. Preoperative Prediction of Pathologic Response After Neoadjuvant Chemoradiotherapy for Pancreatic Ductal Adenocarcinoma: A Metabolic Response-Based Predictive … Co-author DOI 10.1002/jso.70360↗
  2. A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectabl… Co-author DOI 10.1245/s10434-025-18714-7↗
  3. ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and… Co-author DOI 10.1245/s10434-025-18894-2↗
  4. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  5. Predictive role of the prognostic nutritional index in patients with pancreatic ductal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by c… Co-author DOI 10.1002/jhbp.1424↗
  6. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant ch… Co-author DOI 10.1016/j.pan.2024.02.007↗
  7. Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emission tomography in patients with resectabl… Co-author DOI 10.1016/j.pan.2024.08.010↗
  8. Serum Carbohydrate Antigen 19-9 and Metabolite Hypotaurine Are Predictive Markers for Early Recurrence of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002304↗
  9. Prognostic Significance of 18F-FDG PET/CT and Tumor Metabolic Changes in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.17151↗
  10. Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients with Resectable and Borderline Resectable … Co-author DOI 10.3390/jcm13051216↗
  11. P53 immunolabeling in EUS-FNA biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with … Co-author DOI 10.1002/jhbp.1286↗
  12. Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borderline resectable pancreatic ductal adeno… Co-author DOI 10.1016/j.hpb.2022.10.004↗
  13. Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiothe… Co-author DOI 10.1002/jso.26854↗
  14. Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancreatic cancer. Co-author DOI 10.1093/jjco/hyac074↗
  15. Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002011↗
  16. Role of Short-Term Neoadjuvant Chemoradiotherapy for Potentially Resectable Pancreatic Cancer. First author DOI 10.1177/0003134821998671↗
  17. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable p… Co-author DOI 10.1186/s12876-020-01566-8↗
  18. Is surgery after neoadjuvant chemoradiotherapy feasible for elderly patients with resectable or borderline resectable pancreatic ductal adenocarcinoma? Co-author DOI 10.21203/rs.2.21112/v1↗
  19. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvan… Co-author DOI 10.1186/s12893-019-0644-z↗
  20. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer. First author DOI 10.1093/jjco/hyy033↗
  21. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic … First author DOI 10.1245/s10434-017-5921-4↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Oshima · 20 shared papers, 2017–2026 · strength 3.32
  2. Keiichi Okano · 20 shared papers, 2017–2026 · strength 3.32
  3. Toru Shibata · 11 shared papers, 2017–2026 · strength 1.74
  4. Tsutomu Masaki · 12 shared papers, 2017–2024 · strength 1.54
  5. Yasuyuki Suzuki · 11 shared papers, 2017–2023 · strength 1.36
  6. Mina Nagao · 8 shared papers, 2018–2024 · strength 1.32
  7. Shigeo Takahashi · 8 shared papers, 2017–2024 · strength 1.10
  8. Akihito Tsuji · 4 shared papers, 2018–2026 · strength 0.76
  9. Ayaka Shimomura · 3 shared papers, 2022–2024 · strength 0.47
  10. Yukiko Wada · 2 shared papers, 2022–2024 · strength 0.29
  11. Takashi Norikane · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.